What “not FDA-approved” actually means

Updated October 2026 · 5 minute read

“Not FDA-approved” is a statement about review. It tells you what a federal agency has not done: found that a therapy helps, or measured its risks. That is not a technicality.

This is general information for anyone weighing a regenerative clinic, ours or any other. It is not medical or legal advice, and it can't say what is right for you. Your own physician is the person to ask about that.

What FDA approval is

Approval is a review that happens before a product reaches patients. The Food and Drug Administration looks at one specific product and evaluates its safety, its effectiveness and its quality. Only then may it be marketed as approved. A product still in development can be given to people under an investigational application that is in effect with the agency. That is permission to study a product. It is not approval of it.

What the phrase tells you, and what it leaves open

When a therapy is not FDA-approved, it has not come through that review. Take the phrase literally. It tells you three things.

• The FDA has not found that it helps. Weighing that question is the agency's job, and the agency has not said yes.
• The FDA has not weighed its risks. That leaves them less well mapped. It does not make them smaller.
• It is still regulated. Federal rules apply to the product, to whoever supplies it, and to what anyone may say about it.

What it leaves open is everything about you. Whether a therapy is appropriate for you is decided at a consultation, with a clinician. No phrase can answer that.

It also sets a limit on marketing. When a clinic says a product treats, cures or prevents a disease, the FDA has taken that as evidence the product is a drug that needs approval. Regulators read a clinic's website, its videos and its social posts for what a product is intended for, and soft wording such as “may help” has not protected the clinics that leaned on it.

How the FDA regulates human cells and tissues

Products made from human cells or tissues have their own federal rules, in Title 21 of the Code of Federal Regulations, Part 1271. In plain words, those rules sort products onto two paths.

The narrow path

A product stays on the first path only if it passes all four tests. It is barely processed. It is used for the same basic job it did in the donor. It is not combined with anything beyond water, crystalloids, or a sterilizing, preserving or storage agent. And it has no body-wide effect and does not depend on living cells to do its job, unless it is the patient's own tissue, comes from a close blood relative, or is for reproductive use. Products on this path must be registered and listed with the FDA and must follow the tissue rules. They do not need premarket approval.

Everything else

A product that misses any one test, and fits no listed exception, is regulated as a drug, a device or a biological product. For cell products, the FDA says that means an approved license to market one, or an investigational application to study one. The agency's consumer alert puts the general rule in a sentence: “Stem cell products are regulated by FDA, and, generally, all stem cell products require FDA approval.”

Which path a particular product is on is a legal question about that product. No brochure can settle it, and this article does not try to, for the products we use or anyone else's. For a reader, the useful question is shorter. Has the FDA reviewed this product, yes or no?

What the FDA tells consumers

The FDA regulates products made from human cells and tissues, and it has published information for consumers about unapproved regenerative medicine products. We encourage you to read it. It is blunt. It lists the safety concerns the agency has received reports of, and it is written about this whole field, our corner of it included. Two habits follow from what the agency tells consumers.

• Ask about review. In a separate safety notification, the agency's advice to patients is direct: ask whether the FDA has reviewed what you are being offered.
• Read credentials slowly. The FDA says that a listing in the ClinicalTrials.gov database, or the fact that a firm has registered with the agency and listed its product, “does not mean the product is legally marketed.” Registration is a filing a firm makes. Approval is a decision the agency makes.

Compounded medications are a separate case

The same three words apply to prescriptions filled by a compounding pharmacy, for a different reason. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness or quality before they reach patients. Under the federal rule that covers state-licensed compounding pharmacies, a compounded medication is prepared for an identified patient, based on a valid prescription.

That rule is an exemption from FDA approval. It is not FDA approval. And a pharmacy's license is a state's oversight of the pharmacy, not a federal review of each medication it prepares. Peptides in plain language goes further.

The questions this should prompt

None of this tells you what to decide. It tells you what to ask. These questions fit any clinic, and the full checklist has more.

1. Has the FDA reviewed this specific product? If the answer is no, is it said that plainly?
2. What is known about it, and what is not yet known?
3. Where does it come from, and how is it handled before it reaches me?
4. What will the consent form say about risks and alternatives?
5. Will I have the options, the risks, the evidence and the cost in writing, to take home and show my own doctor?
6. Who decides whether I'm a candidate, and what happens if I'm not?
7. In Utah: have you given me the notice Utah requires?

Check it yourself

The FDA publishes a list of the cellular and gene therapy products it has approved. Any product a clinic names can be checked against it.

At Nuvira the phrase comes first, not last. None of our cellular therapies is on that list. Every therapy we discuss is elective and not FDA-approved. Candidacy is decided at consultation, what is known and not yet known is reviewed with you first, and no outcome is promised.